greater than minimal” thrombolysis,
although at the expense of a 2.9-fold increase in major
bleeding complications.13 However, more quantitative
analysis of thrombolytic outcomes has demonstrated complete thrombolysis in as few as 8.9% and no thrombus
reduction in as many as 33.8% of patients treated with
systemic tissue plasminogen activator.14 We recommend
against the use of non– cath